Compare The Coca-Cola Co K (KO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Summit Therapeutics Inc — how do they compare? The Coca-Cola Co K trades at $88.39 (market cap $377.63B), while Summit Therapeutics Inc trades at $17.45 (market cap $13.71B). The key difference: The Coca-Cola Co K is far larger — about 27.5× Summit Therapeutics Inc's market cap, and The Coca-Cola Co K pays a 2.42% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Summit Therapeutics Inc for 16 Days on average.
| KO | SMMT | |
|---|---|---|
Market Cap | $377.63B | $13.71B |
Volume | 14,894,568 | 6,173,057 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $26.38 |
52-Week Low | $66.37 | $12.43 |
Typical Hold Time | 154 Days | 16 Days |
Enterprise Value | $404.81B | $13.04B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $87.97, up 2.51% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong profitability with a 28.56% net income margin and a 44.23% ROE for 2025. Analyst consensus is a Buy with a $95.75 price target, and institutional buying activity is evident in recent news. The stock is positioned near key resistance at $88, with support at $87.
The outlook for KO is positive, driven by consistent earnings performance and a strong dividend history, but risks include high valuation multiples and regional demand volatility. The stock offers stability with growth potential, though investors should monitor debt levels and competitive pressures in the beverage industry.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
